文献
J-GLOBAL ID:201802225821783028
整理番号:18A0720055
二次進行性多発性硬化症(拡大)におけるSiponimod対プラセボ:二重盲検無作為化第3相試験【JST・京大機械翻訳】
Siponimod versus placebo in secondary progressive multiple sclerosis (EXPAND): a double-blind, randomised, phase 3 study
著者 (15件):
Kappos Ludwig
(Neurologic Clinic and Policlinic, Departments of Medicine, Clinical Research, Biomedicine, and Biomedical Engineering, University Hospital, University of Basel, Basel, Switzerland)
,
Bar-Or Amit
(Center for Neuroinflammation and Neurotherapeutics, and Multiple Sclerosis Division, Department of Neurology, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA)
,
Bar-Or Amit
(Neuroimmunology Unit, Montreal Neurological Institute and Hospital, McGill University, Montreal, QC, Canada)
,
Cree Bruce A C
(UCSF Weill Institute for Neurosciences, Department of Neurology, University of California San Francisco, San Francisco, CA, USA)
,
Fox Robert J
(Mellen Centre for Multiple Sclerosis Treatment and Research, Neurological Institute, Cleveland Clinic, Cleveland, OH, USA)
,
Giovannoni Gavin
(Blizard Institute, Barts and The London School of Medicine and Dentistry, Queen Mary University of London, London, UK)
,
Gold Ralf
(Department of Neurology, St Josef-Hospital/Ruhr-University Bochum, Bochum, Germany)
,
Vermersch Patrick
(University of Lille, CHU Lille, LIRIC-INSERM U995, Lille, France)
,
Arnold Douglas L
(Montreal Neurological Institute, McGill University, Montreal, QC, Canada)
,
Arnold Douglas L
(NeuroRx Research, Montreal, QC, Canada)
,
Arnould Sophie
(Novartis Pharma AG, Basel, Switzerland)
,
Scherz Tatiana
(Novartis Pharma AG, Basel, Switzerland)
,
Wolf Christian
(Lycalis, Brussels, Belgium)
,
Wallstrom Erik
(Novartis Pharma AG, Basel, Switzerland)
,
Dahlke Frank
(Novartis Pharma AG, Basel, Switzerland)
資料名:
Lancet
(Lancet)
巻:
391
号:
10127
ページ:
1263-1273
発行年:
2018年
JST資料番号:
B0673A
ISSN:
0140-6736
CODEN:
LANCA
資料種別:
逐次刊行物 (A)
記事区分:
原著論文
発行国:
オランダ (NLD)
言語:
英語 (EN)